Fosmetpantotenate

Drug Profile

Fosmetpantotenate

Alternative Names: RE-024

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Retrophin
  • Class Amino acids; Imides; Neuroprotectants; Phosphates; Small molecules; Vitamins
  • Mechanism of Action Phosphopantothenate replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pantothenate kinase-associated neurodegeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pantothenate kinase-associated neurodegeneration

Most Recent Events

  • 25 Apr 2017 Phase-III clinical trials in Pantothenate kinase-associated neurodegeneration (In children, In adolescents, In adults) in USA (PO) (NCT03041116)
  • 16 Feb 2017 CTP push 268553 (NCT03041116) - Planned trial info already updated; Trial identifiers and qualifiers added
  • 24 Jan 2017 Phase-II clinical trials in Pantothenate kinase-associated neurodegeneration in USA (PO) before January 2017 (Retrophin pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top